We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

National Survey on Gastroesophageal Reflux Disease (GERD) Patients (LINEA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00695838
First Posted: June 12, 2008
Last Update Posted: August 6, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
The purpose of this observational study is to assess the impact of abdominal fat on severity and frequency of GERD symptoms .

Condition
GERD

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Evaluation of the Impact of Abdominal Fat on GERD Severity and GERD Frequency in General Practice

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Waist circumference [ Time Frame: Once ]

Secondary Outcome Measures:
  • Frequency of GERD symptoms [ Time Frame: Once ]
  • GERD impact scale [ Time Frame: Once ]

Enrollment: 5084
Study Start Date: January 2008
Study Completion Date: December 2008

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
First three consecutive patients with GERD symptoms seen by GP
Criteria

Inclusion Criteria:

  • Male or female > or = 18 years old
  • Patient with symptomatic GERD
  • Without PPI or H2 antagonist treatment during the 3 previous months
  • Agree to take part in this study

Exclusion Criteria:

  • Pregnant women
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00695838


  Show 1638 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Alain Castaigne, Medical Director AstraZeneca
  More Information

Responsible Party: Alain Castaigne, Medical Director, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00695838     History of Changes
Other Study ID Numbers: NIS-GFR-DUM-2007/3
First Submitted: June 10, 2008
First Posted: June 12, 2008
Last Update Posted: August 6, 2009
Last Verified: August 2009

Keywords provided by AstraZeneca:
GERD symptoms- Waist circumference
Patients with symptomatic GERD

Additional relevant MeSH terms:
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases